These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26651976)

  • 1. Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs.
    Ragia G; Dahl ML; Manolopoulos VG
    Curr Drug Metab; 2016; 17(3):227-36. PubMed ID: 26651976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
    Beunk L; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw D; van Westrhenen R; Deneer VHM; van der Weide J
    Eur J Hum Genet; 2024 Mar; 32(3):278-285. PubMed ID: 37002327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
    Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
    Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.
    Kalgutkar AS; Taylor TJ; Venkatakrishnan K; Isin EM
    Drug Metab Dispos; 2003 Mar; 31(3):243-9. PubMed ID: 12584149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.
    Bakken GV; Rudberg I; Christensen H; Molden E; Refsum H; Hermann M
    Drug Metab Dispos; 2009 Feb; 37(2):254-8. PubMed ID: 19022943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.
    Kim KA; Joo HJ; Lee HM; Park JY
    Pharmacogenet Genomics; 2014 Jan; 24(1):35-42. PubMed ID: 24240480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
    Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
    Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin regulation of CYP3A4 and CYP3A5 expression.
    Willrich MA; Hirata MH; Hirata RD
    Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.
    Shilbayeh SA; Sy SK; Melhem M; Zmeili R; Derendorf H
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):387-94. PubMed ID: 27137148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamazepine 10,11-epoxidation in human liver microsomes: influence of the
    Miyata-Nozaka Y; Zain SM; Taguchi M; Shigeyama M; Isobe T; Hanioka N
    Pharmazie; 2017 Dec; 72(12):747-750. PubMed ID: 29441960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates.
    Saiz-Rodríguez M; Almenara S; Navares-Gómez M; Ochoa D; Román M; Zubiaur P; Koller D; Santos M; Mejía G; Borobia AM; Rodríguez-Antona C; Abad-Santos F
    Biomedicines; 2020 Apr; 8(4):. PubMed ID: 32331352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants.
    Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Jiang-Zheng C; Koller D; Mejía G; Zubiaur P; Wojnicz A; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):474-485. PubMed ID: 29723928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
    Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
    Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.